Sign In
Buy ELVN
Enliven Therapeutics Stock Insider Power
Based on the 100 latest insides trades, we have calculated the insider power to be negative at -92.25. In total, the insiders bought 1.38M and sold 1.71M ELVN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.
Insider Power
|
-92.25 |
| ● Buy | 1.38M shares |
| ● Sell | 1.71M shares |
|
46% Buy Activity
Weak Negative Correlation
|
|
Historical Insider Trades
| Date | Type | Person | Role | Amount |
|---|---|---|---|---|
|
Apr 17, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
5 000 Value: $12.4K |
||
|
Apr 17, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
5 000 Value: $12.4K |
||
|
Apr 17, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
2 419 Value: $114.6K |
||
|
Apr 17, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
2 441 Value: $117.3K |
||
|
Mar 25, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
40 000 Value: $99.2K |
||
|
Mar 25, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
40 000 Value: $99.2K |
||
|
Mar 25, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
40 000 Value: $1.40M |
||
|
Mar 17, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
5 000 Value: $138.8K |
||
|
Mar 17, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
5 000 Value: $12.4K |
||
|
Mar 17, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
5 000 Value: $12.4K |
||
|
Mar 10, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
10 129 Value: $305.8K |
||
|
Mar 10, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
10 129 Value: $25.1K |
||
|
Mar 10, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
10 129 Value: $25.1K |
||
|
Mar 09, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
29 871 Value: $74.1K |
||
|
Mar 09, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
29 871 Value: $74.1K |
||
|
Mar 09, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
29 871 Value: $896.8K |
||
|
Mar 06, 2026 Sell |
Hohl Benjamin Chief Financial Officer |
10 000 Value: $295.8K |
||
|
Feb 17, 2026 Sell |
Collins Helen Louise Chief Medical Officer |
45 000 Value: $1.18M |
||
|
Feb 17, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
45 000 Value: $111.6K |
||
|
Feb 17, 2026 Sell |
Heyman Richard A. Director |
1 230 Value: $32.2K |
||
|
Feb 17, 2026 Buy |
Collins Helen Louise Chief Medical Officer |
45 000 Value: $111.6K |
||
|
Feb 12, 2026 Buy |
Hohl Benjamin Chief Financial Officer |
25 000 Value: $679.0K |
||
|
Feb 12, 2026 Buy |
Hohl Benjamin Chief Financial Officer |
150 000 Value: $4.07M |
||
|
Feb 12, 2026 Buy |
Patel Anish Chief Operating Officer |
20 000 Value: $543.2K |
||
|
Feb 12, 2026 Buy |
Patel Anish Chief Operating Officer |
120 000 Value: $3.26M |
About Insider Power
Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.
It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.
While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.
* October 6th, 2025 - Tested on 5562 stocks
